微生物组在自身免疫性肝病中的作用
综述阐述微生物组在自身免疫性肝病(自身免疫性肝炎、原发性胆汁性胆管炎、原发性硬化性胆管炎)中的作用,指出所有自身免疫性肝病均与肠道微生物组多样性降低及特定细菌丰度改变相关,但微生物组与肝病的关系是双向的且随疾病进程变化,难以区分因果关系;潜在机制包括致病共生菌、改变疾病的微生物代谢物及非特异性肠道屏障功能降低;肝移植后疾病复发是主要临床挑战,也可能是研究肠-肝轴疾病机制的窗口;提出未来研究方向包括临床试验、高分辨率分子表型分析和模型系统实验研究。
要点
- 所有自身免疫性肝病均与肠道微生物组多样性降低及特定细菌丰度改变相关。
- 微生物组与肝病的关系是双向的且随疾病进程变化,难以区分是起始因素还是继发改变。
- 肝移植后疾病复发是主要临床挑战,也可能是研究肠-肝轴疾病机制的窗口。
核心结论
- 自身免疫性肝病的特征是微生物组改变,针对这些改变的干预基于新兴的微生物组医学领域有望改善临床诊疗。
研究设计与样本
- 综述,未报告检索范围。
主要发现
- 所有自身免疫性肝病均与肠道微生物组多样性降低及特定细菌丰度改变相关。
- 微生物组与肝病的关系是双向的且随疾病进程变化。
- 难以区分微生物组改变是自身免疫性肝病的起始或驱动因素、疾病和/或药物干预的继发后果,还是改变患者临床病程的变异。
- 潜在机制包括致病共生菌的存在、改变疾病的微生物代谢物以及更非特异性的肠道屏障功能降低。
- 这些改变的影响很可能在疾病进展过程中发生变化。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The microbiome plays a crucial role in integrating environmental influences into host physiology, potentially linking it to autoimmune liver diseases, such as autoimmune hepatitis, primary biliary cholangitis, and primary sclerosing cholangitis. All autoimmune liver diseases are associated with reduced diversity of the gut microbiome and altered abundance of certain bacteria. However, the relationship between the microbiome and liver diseases is bidirectional and varies over the course of the disease. This makes it challenging to dissect whether such changes in the microbiome are initiating or driving factors in autoimmune liver diseases, secondary consequences of disease and/or pharmacological intervention, or alterations that modify the clinical course that patients experience. Potential mechanisms include the presence of pathobionts, disease-modifying microbial metabolites, and more nonspecific reduced gut barrier function, and it is highly likely that the effect of these change during the progression of the disease. Recurrent disease after liver transplantation is a major clinical challenge and a common denominator in these conditions, which could also represent a window to disease mechanisms of the gut-liver axis. Herein, we propose future research priorities, which should involve clinical trials, extensive molecular phenotyping at high resolution, and experimental studies in model systems. Overall, autoimmune liver diseases are characterized by an altered microbiome, and interventions targeting these changes hold promise for improving clinical care based on the emerging field of microbiota medicine.
引用
- Schneider KM, Kummen M, Trivedi PJ, et al. Role of microbiome in autoimmune liver diseases. Hepatology. 2023. PMID: 37369002. doi:10.1097/HEP.0000000000000506
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。